Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension

Figures & data

Table 1 Demographic and baseline characteristics

	Brinzolamide/timolol (n = 58)	Dorzolamide/timolol (n = 57)	P-value
Age, years			0.5818a
Mean (standard deviation)	64.2 (13.6)	65.7 (15.7)
Range (minimum, maximum)	(22, 85)	(19, 89)
Sex, n (%)			0.2159b
Men	17 (29.3)	24 (42.1)
Women	41 (70.7)	33 (57.9)
Race, n (%)			>0.999c
White	46 (79.3)	46 (80.7)
Hispanic	10 (17.2)	10 (17.5)
Black	1 (1.7)	1 (1.8)
Asian	1 (1.7)	0 (0.0)
Glaucoma diagnosis, n (%)			0.7167c
Ocular hypertension	3 (5.2)	4 (7.0)
Primary open-angle glaucoma	55 (94.8)	53 (93.0)
Intraocular pressure, mmHg			0.3706a
Mean (standard deviation)	15.9 (3.3)	15.6 (2.5)
Range (minimum, maximum)	(9–27)	(8–22)

Notes: Treatment groups were based on the randomization assignment for day 1, or the per-protocol population.

a P-value calculated from a t-test;

b P-value calculated from a Chi-square test;

c P-value calculated from a Fisher’s exact test.

Figure 1 Patient preference for study medication.

Notes: On day 2, of the 115 patients in the per-protocol population, three expressed no preference for one study drug over the other; these patients are not included in the figure. *Significant difference between treatments; P < 0.001 (n = 112; per-protocol population). P-value was calculated from a Chi-square test.

Figure 2 Mean ocular discomfort scores with standard error of the mean error bars after instillation of brinzolamide/timolol or dorzolamide/timolol.

Notes: Data from day 1 and day 2 were combined; lower scores indicate less discomfort. Data are mean ocular discomfort scores ± standard error of the mean. *Significant difference between treatments; P = 0.00014 (n = 115; per-protocol population). P-value was calculated from a Chi-square test.